Current treatment options for patients experiencing a stroke or heart attack are limited and delay the
re-establishment of blood flow.
TSci is dedicated to transforming standards of care, by bringing a simple intravenous biotherapy to the patient, closer to the time of onset.
TSci's bio-inspired solution is
A low dose, efficacious, safer dual thrombolytic Rx
Based on a clinically validated mechanism
To be given on suspicion of a stroke or heart attack
tPA's biological role is limited to degrading the surface of the clot.
With TSci’s regimen, once this occurs, the small amount of tPA used is rapidly cleared from the blood flow. HisproUK, TSci's compound, exclusively targets the now degraded clot and dissolves it.
Should there be no degraded clot, as in the case of stroke mimics or a hemorrhagic stroke, HisproUK will remain safely in its inactive pro enzymatic form before being cleared in minutes from the blood flow.
TSci's thrombolytic regimen could therefore be given safely on simple suspicion of an ischemic stroke, as soon as possible after stroke onset.
Management & Directors
Alexis Wallace, MScEng, MBA
Chief Executive Officer,
Co-founder & Board member
Chief Scientific Officer,
of the Board
Chairman of the Court,
London School of Hygiene
& Tropical Medicine
Professor of Medicine, Hematology
Adjunct Professor, Neurology,
Harvard Medical School, Former Chief Medical Officer, Chairman & Founder, InfraReDx
1985 Nobel Peace Prize
President & CEO,
for Clinical Research
Professor of Medicine,
Harvard Medical School
Chairman & Founder, PERFUSE
May 22, 2023
No significant difference between groups in All ICH, i.e.: asymptomatic + symptomatic ICH, the primary endpoint.
Secondary endpoints show positive trends in favor of a safe, low dose dual therapy
No symptomatic ICH
No fibrinogen depletion, i.e.: less risk of bleeding
Authors conclude further exploration in more severe stroke patients is warranted.
December 02, 2022
Thrombolytic Science submits an IND to FDA
October 29, 2021
February 10, 2021
Thrombolytic Science Reinforces Its IP Portfolio with Patents in Europe, the Commonwealth of Independent States and Japan. New Patents to Support Global Partnering of Novel Bio-inspired Clot-dissolving Therapy
October 30, 2019
September 5, 2018
November 15, 2017
September 18, 2017
VIEW> Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. PLoS One. 2011; 6(7):e21999
Thrombolytic Science, LLC
One Broadway, 14 FL
Cambridge, MA 02142